One such avenue is through the protein tyrosine phosphatase non-receptor type 2 (PTPN2) and its close superfamily member, PTPN1, identified in previous research as crucial modulators involved in ...

and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) targeting moiety through a linker reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic ...

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and ...

Insilico's compound demonstrated enhanced oral absorption, systemic exposure, and equivalent biological activities compared to the reference compound in in vitro studies.

The clinical-stage projects include two immuno-oncology candidates in phase 1 testing – both PTPN2 inhibitors – that "act at multiple steps in the cancer immunity cycle", and a drug for a ...